Placebo + vinorelbine

Vinorelbine is a semi-synthetic vinca alkaloid chemotherapy drug used primarily to treat non-small cell lung cancer (NSCLC) and advanced or metastatic breast cancer. It works as a mitotic inhibitor by binding to tubulin in microtubules, thereby inhibiting their polymerization and blocking cell division at metaphase. This action disrupts the mitotic spindle formation necessary for chromosome segregation during cell division, leading to apoptosis of rapidly dividing cancer cells. Vinorelbine can be administered orally (as capsules) or intravenously and is often used alone or in combination with other chemotherapeutic agents[1][2][4][5]. Placebo + vinorelbine refers specifically to the use of both an inactive placebo agent and active vinorelbine within a clinical trial context—typically as part of randomized controlled studies evaluating efficacy and safety versus placebo control.